Abstract: The present disclosure relates to new crystal forms of chemical compounds, formulations including, methods of forming, and methods of using same.

Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Abstract: The present invention discloses anti-PD-L/PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor/cancer.

Abstract: Described herein are 2-amino-quinoline derivatives that are agonists of toll-like receptors 7 and 8 (TLR7/8), pharmaceutical compositions, and methods of use of the compounds and compositions to treat various diseases, such as viral, cancer, and allergic diseases, in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative.

Abstract: Described herein are 2-amino-quinoline derivatives that are agonists of toll-like receptors 7 and 8 (TLR7/8), pharmaceutical compositions, and methods of use of the compounds and compositions to treat various diseases, such as viral, cancer, and allergic diseases, in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative.

Abstract: Described herein are 2-amino-quinoline derivatives that are agonists of toll-like receptors 7 and 8 (TLR7/8), pharmaceutical compositions, and methods of use of the compounds and compositions to treat various diseases, such as viral, cancer, and allergic diseases, in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative.

Abstract: A combination which comprises an effective amount of Her2/Neu antagonist and an effective amount of immunotherapeutic that is capable of activating a human plasmacytoid dendritic cell, myeloid dendritic cell, NK cell, or a combination thereof is disclosed.

Abstract: A method for identifying a pattern of a load cycle includes: performing statistics on a daily load of a system based on smart meter data; generating a curve of the daily load of the system according to the statistics on the daily load of the system; acquiring a result of clustering curves of loads of typical days by applying shape-based time sequence clustering analysis using the curve of the daily load of the system; and identifying a pattern of a load cycle according to the result of clustering the curves of the loads of the typical days.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

Abstract: A method and an apparatus for determining the distributed power supply capacity to be accessed by a feed line of a power distribution network, and a storage medium, the method comprising: determining feed line loss on the basis of load information of power distribution network feed line access nodes and circuit parameters; on the basis of the feed line loss, determining three-phase voltage change values of the feed line circuit; using a single phase having the greatest voltage change amongst the voltage change values, determining a maximum active power for distributed power supply access under voltage constraints; comparing the current of the feed line corresponding to the maximum active power with a circuit current limit, and determining the distributed power supply capacity to be accessed by the feed line; the apparatus comprises a feed line information collection unit, a voltage drop unit, a quantitative calculation unit, and a results analysis unit.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of HER2 positive tumors/cancers.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.

Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.

Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of EGFR expressing tumors/cancers.

Abstract: Described herein are 2-amino-quinoline derivatives that are agonists of toll-like receptors 7 and 8 (TLR7/8), pharmaceutical compositions, and methods of use of the compounds and compositions to treat various diseases, such as viral, cancer, and allergic diseases, in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative.

Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of EGFR expressing tumors/cancers. Also provided are compositions comprising the compounds.